Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 15/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 14/20 | 0.45 |
| ▸ | ADK | P55263 | 1/20 | 0.41 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.38 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.38 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14081718 | 1.00 | PRMT5 (0.45) | PRMT5WDR77ADKDNMT1DNMT3B | |
| SCHEMBL13598729 | 0.89 | ALDH1A1 (0.38) | PRMT5WDR77 | |
| SCHEMBL4011551 | 0.89 | ALDH1A1 (0.38) | PRMT5WDR77 | |
| SCHEMBL1737262 | 0.87 | XDH (0.39) | PRMT5WDR77ADK | |
| SCHEMBL13650039 | 0.84 | ENPP1 (0.32) | PRMT5WDR77 | |
| SCHEMBL13839395 | 0.84 | ENPP1 (0.32) | PRMT5WDR77 | |
| SCHEMBL13302001 | 0.84 | PRMT5 (0.45) | PRMT5WDR77ADKDNMT1DNMT3B | |
| SCHEMBL13494110 | 0.84 | ADK (0.38) | ADK | |
| SCHEMBL16497062 | 0.82 | ADK (0.41) | PRMT5ADKMETTL3 | |
| SCHEMBL16496534 | 0.81 | ADK (0.36) | ADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010015637-A1 | NEW ANTIVIRAL MODIFIED NUCLEOSIDES | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | disclosed |
| US-20090253648-A1 | Tricyclic-Nucleoside Compounds for Treating Viral Infections | SMITHKLINE BEECHAM CORPORATION (US) | 2009-10-08 | — | — | US | disclosed |
| US-7524825-B2 | Tricyclic-nucleoside compounds for treating viral infections | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-20090048189-A1 | TRICYCLIC-NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. | 2009-02-19 | — | — | US | disclosed |
| US-7414031-B2 | 5-nitro-nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-20060252715-A1 | Tricyclic-nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. | 2006-11-09 | — | — | US | disclosed |
| US-20060111311-A1 | 5-nitro-nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048189-A1 | TRICYCLIC-NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | TYMP, PNP, NSUN2 | PRMT5 2728/4885WDR77 1611/4885ADK 944/4885 |
| US-20060111311-A1 | 5-nitro-nucleoside compounds for treating viral infections | PNP, NT5C3B, NSUN2 | PRMT5 255/4885WDR77 2772/4885ADK 596/4885 |
| US-20060252715-A1 | Tricyclic-nucleoside compounds for treating viral infections | PNP, TYMP, NSUN2 | PRMT5 3135/4885WDR77 2076/4885ADK 365/4885 |
| US-20090253648-A1 | Tricyclic-Nucleoside Compounds for Treating Viral Infections | PNP, TYMP, NSUN2 | PRMT5 3135/4885WDR77 2076/4885ADK 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.